A Phase I clinical study of the safety, tolerability, pharmacokinetic characteristics, and food effects of single/multiple doses of TDI01 suspension in healthy Chinese subjects
Latest Information Update: 18 Mar 2026
At a glance
- Drugs TDI 01 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacokinetics
Most Recent Events
- 18 Mar 2026 New trial record